Tinostamustine

N/A

Report date: 2025/11/17 15:20:23
NME

Base Information

Drug NameTinostamustine
Drug Alias NameBendamustine-vorinostat fusion moleculeCY-190602EDO-S101NL-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 2 inhibitorsHistone deacetylase 6 inhibitorsHistone deacetylase 3 inhibitors +[4] 
TargetsHistone deacetylase 2Histone deacetylase 1Histone deacetylase 3 +[4] 
Therapy Area/IndicationsEndometrial NeoplasmsSmall Cell Lung CarcinomaHematologic Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMundipharma Edo Gmbh
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMundipharma Research LtdThe University Of Texas MD Anderson Cancer CenterHangzhou Minsheng Pharmaceutical Co Ltd +[4] 
Inactive CompaniesMundipharma Edo Gmbh
Active IndicationsEndometrial NeoplasmsSmall Cell Lung CarcinomaHematologic Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A